Development
Ekso Bionics Holdings, Inc.
EKSO
$3.14
-$0.11-3.39%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 18.28M | 16.98M | 15.71M | 14.47M | 12.91M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.28M | 16.98M | 15.71M | 14.47M | 12.91M |
| Cost of Revenue | 9.20M | 8.60M | 8.09M | 7.46M | 6.70M |
| Gross Profit | 9.08M | 8.39M | 7.62M | 7.01M | 6.21M |
| SG&A Expenses | 19.72M | 20.44M | 20.66M | 19.52M | 18.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.39M | 33.08M | 32.53M | 30.23M | 28.47M |
| Operating Income | -15.11M | -16.10M | -16.82M | -15.77M | -15.56M |
| Income Before Tax | -15.20M | -15.16M | -16.10M | -14.85M | -15.08M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.20 | -15.16 | -16.10 | -14.85 | -15.08 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.20M | -15.16M | -16.10M | -14.85M | -15.08M |
| EBIT | -15.11M | -16.10M | -16.82M | -15.77M | -15.56M |
| EBITDA | -13.41M | -14.82M | -15.72M | -14.70M | -14.67M |
| EPS Basic | -1.10 | -1.12 | -1.21 | -1.13 | -1.16 |
| Normalized Basic EPS | -0.69 | -0.70 | -0.76 | -0.71 | -0.73 |
| EPS Diluted | -1.11 | -1.12 | -1.21 | -1.13 | -1.16 |
| Normalized Diluted EPS | -0.69 | -0.70 | -0.76 | -0.71 | -0.73 |
| Average Basic Shares Outstanding | 55.45M | 54.17M | 53.16M | 52.41M | 51.84M |
| Average Diluted Shares Outstanding | 55.45M | 54.17M | 53.16M | 52.41M | 51.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |